Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Dr Ashutosh Mukherji
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 18 years or older. Histologically confirmed diffuse adult type high grade gliomas WHO Grade 3 or WHO Grade 4 and IDH wild type adult diffuse Grade 2 gliomas as per WHO 2021 classification. IDH wild type adult diffuse gliomas meeting molecular criteria for glioblastoma WHO Grade 4. Patients who have undergone surgical resection or biopsy followed by curative intent radiotherapy with or without chemotherapy. Patients treated at MPMMCC and HBCH Varanasi or referred for curative intent radiotherapy. Availability of complete clinical radiological pathological and treatment records. Availability of radiotherapy planning and dosimetric data in ARIA Eclipse for relevant analyses. Patients willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: Low grade gliomas WHO Grade 1 or WHO Grade 2 and pediatric type gliomas. Gliomas of the brainstem optic pathway or spinal cord. Non diffuse or circumscribed gliomas as per WHO 2021 classification. Recurrent gliomas previously treated with cranial radiotherapy. Patients who received definitive treatment entirely outside the study institution without adequate records. Patients with concurrent malignancies affecting survival outcomes. Patients unwilling or unable to provide informed consent for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival defined as the time from surgery to first documented disease progression recurrence or death from any cause whichever occurs first.Timepoint: Up to 18 months from date of inclusion or until disease progression recurrence death or end of study whichever occurs earlier. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival at 18 months.Timepoint: 18 months after inclusion or until death whichever occurs earlier.;Patterns of disease recurrence including local marginal and distant recurrence.Timepoint: Assessed throughout follow up up to 18 months.;Treatment related toxicities including radionecrosis gliosis and chemotherapy related toxicities.Timepoint: Assessed throughout follow up up to 18 months. | — |
Countries
India
Contacts
Public ContactAshutosh Mukherji
Mahamana Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital Varanasi
Outcome results
None listed